Alaunos Therapeutics to Present at the H.C. Wainwright Global Investment Conference
Alaunos Therapeutics (Nasdaq: TCRT) will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alaunos Therapeutics (Nasdaq: TCRT) will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, from 5:00-5:30 PM ET at the Fontainebleau Miami Beach Hotel. The presentation will be delivered by CEO Kevin S. Boyle Sr. and VP of R&D Drew Deniger, Ph.D. A live webcast will be available on the company's website, with replays accessible for 90 days. Alaunos focuses on T-cell receptor therapies for oncology, utilizing its proprietary Sleeping Beauty gene transfer technology and collaborating with leading cancer research institutions.
Details
News Market Reaction – TCRT
The recorded move for TCRT in the trading session of this news was +6.16%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOUSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced that Kevin S. Boyle Sr., Chief Executive Officer and Drew Deniger, Ph.D., Vice President, Research & Development at Alaunos Therapeutics will present at the upcoming H.C. Wainwright Global Investment Conference being held on May 23-26, 2022 in Miami Beach, FL.
Details for the presentations are below:
Event: H.C. Wainwright Global Investment Conference
Date: Tuesday, May 24, 2022
Time: 5:00-5:30 pm ET
Location: Fontainebleau Miami Beach Hotel
Room: Splash 10
A live webcast of the presentation will be accessible on the Company’s website in the Investors section under Events & Presentations at www.alaunos.com or by using the link here. A replay of the webcast will be available on the Alaunos website for approximately 90 days following the presentation.
About Alaunos Therapeutics
Alaunos is a clinical-stage oncology-focused cell therapy company, focused on developing T-cell receptor (TCR) therapies based on its proprietary, non-viral Sleeping Beauty gene transfer technology and its TCR library targeting shared tumor-specific hotspot mutations in key oncogenic genes including KRAS, TP53 and EGFR. The Company has clinical and strategic collaborations with The University of Texas MD Anderson Cancer Center and the National Cancer Institute. For more information, please visit www.alaunos.com.
Investor Relations Contact:
Alex Lobo
Stern Investor Relations
Alex.lobo@sternir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.